{"id":11508,"date":"2022-02-28T10:34:34","date_gmt":"2022-02-28T15:34:34","guid":{"rendered":"https:\/\/www.med.unc.edu\/genetics\/?p=11508"},"modified":"2022-02-28T10:34:34","modified_gmt":"2022-02-28T15:34:34","slug":"heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/","title":{"rendered":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy"},"content":{"rendered":"<p class=\"lead\">The compound CMX521 significantly reduced lung viral titer and symptoms in a SARS-CoV-2 mouse model, as reported by biomedical company Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at UNC-Chapel Hill. UNC School of Medicine faculty Nat Moorman, PhD, and Mark Heise, PhD, are key researchers in this program.<\/p>\n<hr \/>\n<figure id=\"25005\" class=\"thumbnail wp-caption alignright featured-image\"><a href=\"https:\/\/news.unchealthcare.org\/wp-content\/uploads\/sites\/1159\/2022\/02\/Moorman_heise_1.jpg\" data-slb-active=\"1\" data-slb-asset=\"434811094\" data-slb-internal=\"0\" data-slb-group=\"24997\"><img loading=\"lazy\" decoding=\"async\" class=\"attachment-medium size-medium wp-post-image\" src=\"https:\/\/news.unchealthcare.org\/wp-content\/uploads\/sites\/1159\/2022\/02\/Moorman_heise_1-300x185.jpg\" alt=\"\" width=\"300\" height=\"185\" \/><\/a><figcaption class=\"caption wp-caption-text\">Nat Moorman, PhD, and Mark Heise, PhD<\/figcaption><\/figure>\n<p>Chimerix\u00a0in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina at Chapel Hill, announced that preclinical data from the company\u2019s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022.<\/p>\n<p>\u201cThe joint effort between the research teams at both Chimerix and READDI has led to these very promising early results in an animal model that we believe supports rapid advancement of CMX521 to clinical proof-of-concept against SARS-CoV-2 where there remains a need for novel therapies with improved efficacy, safety and\/or resistance profiles,\u201d said Mike Sherman, CEO of Chimerix. \u201cThis agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.\u201d<\/p>\n<p>John Bamforth, PhD, of READDI and Director of the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy, said, \u201cThese compelling data encourage us to further investigate the potential of CMX521 as a prophylactic and as a therapeutic for SARS-CoV-2 infection. We are very excited about these data and also look forward to READDI\u2019s ongoing mission to identify novel antivirals active against entire families of viruses, including coronaviruses, flaviviruses and alphaviruses.\u201d<\/p>\n<p>Chimerix is investigating CMX521 under a research agreement with UNC School of Medicine researchers\u00a0<a href=\"https:\/\/www.med.unc.edu\/microimm\/directory\/nat-morman-phd\/\">Nat Moorman, PhD<\/a>, associate professor in the UNC Department of Microbiology &amp; Immunology, and\u00a0<a href=\"https:\/\/www.med.unc.edu\/genetics\/directory\/mark-heise-phd\/\">Mark Heise, PhD<\/a>, professor in the UNC Department of Genetics and the UNC Department of Microbiology &amp; Immunology.<\/p>\n<p>Read the\u00a0<a href=\"https:\/\/ir.chimerix.com\/news-releases\/news-release-details\/chimerix-collaboration-rapidly-emerging-antiviral-drug\">press release<\/a>\u00a0from Chimerix.<\/p>\n<p><strong>About READDI<\/strong><\/p>\n<p><a href=\"https:\/\/www.readdi.org\/about-us.html\">Rapidly Emerging Antiviral Drug Development Initiative<\/a>\u00a0is a global public-private partnership founded at the University of North Carolina Chapel Hill by the UNC Eshelman School of Pharmacy, UNC School of Medicine, the UNC Gillings School of Global Public Health, the Eshelman Institute for Innovation, and the Structural Genomics Consortium. READDI was created to generate new broad-spectrum antiviral therapies to save lives in the current COVID-19 pandemic and to prevent emerging viral threats from becoming global catastrophes.<\/p>\n<p>&nbsp;<\/p>\n<p><em>**This article originally appeared in the <a href=\"https:\/\/news.unchealthcare.org\/2022\/02\/chimerix-readdi-at-unc-announce-preclinical-data-on-covid-anti-viral-treatment\/\">UNC Health and UNC School of Medicine Newsroom<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The compound CMX521 significantly reduced lung viral titer and symptoms in a SARS-CoV-2 mouse model, as reported by biomedical company Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at UNC-Chapel Hill. UNC School of Medicine faculty Nat Moorman, PhD, and Mark Heise, PhD, are key researchers in this program.<\/p>\n","protected":false},"author":28418,"featured_media":9368,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[100],"class_list":["post-11508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-heise","odd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics\" \/>\n<meta property=\"og:description\" content=\"The compound CMX521 significantly reduced lung viral titer and symptoms in a SARS-CoV-2 mouse model, as reported by biomedical company Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at UNC-Chapel Hill. UNC School of Medicine faculty Nat Moorman, PhD, and Mark Heise, PhD, are key researchers in this program.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Genetics\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-28T15:34:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"365\" \/>\n\t<meta property=\"og:image:height\" content=\"365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jonathon Cornett\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jonathon Cornett\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\"},\"author\":{\"name\":\"Jonathon Cornett\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/0291e0ce388bbf007b03c591fc542716\"},\"headline\":\"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy\",\"datePublished\":\"2022-02-28T15:34:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\"},\"wordCount\":421,\"publisher\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg\",\"keywords\":[\"Heise\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\",\"name\":\"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg\",\"datePublished\":\"2022-02-28T15:34:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg\",\"width\":365,\"height\":365,\"caption\":\"Mark Heise\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/genetics\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/\",\"name\":\"UNC Department of Genetics\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/genetics\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#organization\",\"name\":\"UNC Department of Genetics\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2018\/11\/Genetics_logo_png_h.png\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2018\/11\/Genetics_logo_png_h.png\",\"width\":982,\"height\":151,\"caption\":\"UNC Department of Genetics\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/0291e0ce388bbf007b03c591fc542716\",\"name\":\"Jonathon Cornett\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/98e4bc231fa6040a28baebf18731553c0d5371994059fc719ab66b8c323ce609?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/98e4bc231fa6040a28baebf18731553c0d5371994059fc719ab66b8c323ce609?s=96&d=mm&r=g\",\"caption\":\"Jonathon Cornett\"},\"description\":\"Genetics\",\"url\":\"https:\/\/www.med.unc.edu\/genetics\/author\/jcornett\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics","og_description":"The compound CMX521 significantly reduced lung viral titer and symptoms in a SARS-CoV-2 mouse model, as reported by biomedical company Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at UNC-Chapel Hill. UNC School of Medicine faculty Nat Moorman, PhD, and Mark Heise, PhD, are key researchers in this program.","og_url":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/","og_site_name":"Department of Genetics","article_published_time":"2022-02-28T15:34:34+00:00","og_image":[{"width":365,"height":365,"url":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","type":"image\/jpeg"}],"author":"Jonathon Cornett","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jonathon Cornett","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/"},"author":{"name":"Jonathon Cornett","@id":"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/0291e0ce388bbf007b03c591fc542716"},"headline":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy","datePublished":"2022-02-28T15:34:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/"},"wordCount":421,"publisher":{"@id":"https:\/\/www.med.unc.edu\/genetics\/#organization"},"image":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","keywords":["Heise"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/","url":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/","name":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy | Department of Genetics","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/genetics\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","datePublished":"2022-02-28T15:34:34+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#primaryimage","url":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","contentUrl":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","width":365,"height":365,"caption":"Mark Heise"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/genetics\/heise-lab-partners-with-chimerix-on-new-sars-cov-2-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/genetics\/"},{"@type":"ListItem","position":2,"name":"Heise Lab Partners with Chimerix on New SARS-CoV-2 Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/genetics\/#website","url":"https:\/\/www.med.unc.edu\/genetics\/","name":"UNC Department of Genetics","description":"","publisher":{"@id":"https:\/\/www.med.unc.edu\/genetics\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/genetics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.med.unc.edu\/genetics\/#organization","name":"UNC Department of Genetics","url":"https:\/\/www.med.unc.edu\/genetics\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/logo\/image\/","url":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2018\/11\/Genetics_logo_png_h.png","contentUrl":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2018\/11\/Genetics_logo_png_h.png","width":982,"height":151,"caption":"UNC Department of Genetics"},"image":{"@id":"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/0291e0ce388bbf007b03c591fc542716","name":"Jonathon Cornett","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/genetics\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/98e4bc231fa6040a28baebf18731553c0d5371994059fc719ab66b8c323ce609?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/98e4bc231fa6040a28baebf18731553c0d5371994059fc719ab66b8c323ce609?s=96&d=mm&r=g","caption":"Jonathon Cornett"},"description":"Genetics","url":"https:\/\/www.med.unc.edu\/genetics\/author\/jcornett\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304-300x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/genetics\/wp-content\/uploads\/sites\/481\/2020\/10\/Mark-Heise-e1601562562304-150x150.jpg","featured_image_alt":"Mark Heise","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/genetics\/category\/news\/"}],"tag_details":[{"name":"Heise","link":"https:\/\/www.med.unc.edu\/genetics\/tag\/heise\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/posts\/11508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/users\/28418"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/comments?post=11508"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/posts\/11508\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/media\/9368"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/media?parent=11508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/categories?post=11508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/genetics\/wp-json\/wp\/v2\/tags?post=11508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}